Mizoguchi Kenji, Hatakeyama Hiromitsu, Yanagida Saori, Nishizawa Noriko, Oridate Nobuhiko, Fukuda Satoshi, Homma Akihiro
Department of Otolaryngology, Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, 060-8638, Japan.
Department of Communication Disorders, School of Psychological Sciences, Health Sciences University of Hokkaido, Sapporo, Hokkaido, Japan.
Eur Arch Otorhinolaryngol. 2017 May;274(5):2215-2223. doi: 10.1007/s00405-017-4463-5. Epub 2017 Feb 22.
Type II thyroplasty (TPII) is one of the surgical options offered in the management of adductor spasmodic dysphonia (AdSD); however, there have been no detailed reports of its safety and associated complications during the perioperative period. Our aim was to assess the complications and safety of TPII. TPII was performed for consecutive 15 patients with AdSD from April 2012 through May 2014. We examined retrospectively the perioperative complications, the degree of surgical invasion, and recovery process from surgery. All patients underwent successful surgery under only local anesthesia. Vocal fold erythema was observed in 14 patients and vocal fold edema in 10 patients; however, all of them showed complete resolution within 1 month. No patient experienced severe complications such as acute airway distress or hemorrhage. Fourteen patients were able to have oral from the 1st postoperative morning, with the remaining patient able to have oral intake from the 2nd postoperative day. In addition, no patient experienced aspiration postoperatively. In conclusion, only minor complications were observed in association with TPII in this study. No dysphagia was observed postoperatively, which is an advantage over other treatments. The results of our study suggest that TPII is a safe surgical treatment for AdSD.
II型甲状成形术（TPII）是内收性痉挛性发声障碍（AdSD）治疗中的手术选择之一；然而，关于其围手术期安全性及相关并发症尚无详细报道。我们的目的是评估TPII的并发症及安全性。2012年4月至2014年5月，对15例连续性AdSD患者实施了TPII。我们回顾性研究了围手术期并发症、手术侵袭程度及术后恢复过程。所有患者仅在局部麻醉下手术成功。14例患者出现声带红斑，10例患者出现声带水肿；然而，所有这些均在术后１个月内完全消退。无患者发生急性气道窘迫或出血等严重并发症。14例患者术后第1天即可经口进食，其余1例患者术后第2天经口进食。此外，无患者术后发生误吸。总之，本研究中TPII仅伴有轻微并发症。术后未观察到吞咽困难，这是相对于其他治疗方法的一个优势。我们的研究结果表明，TPII是一种治疗AdSD的安全手术方法。
